PR-201

N/A

Report date: 2025/12/10 14:21:16

Base Information

Drug NamePR-201
Drug Alias NamePR201PR-201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-PD-1Interleukin-2 modulators
TargetsProgrammed cell death protein 1Interleukin-2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesLuye Pharma Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLuye Pharma Group Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A